Inovio Pharmaceuticals, Inc.

NasdaqCM:INO Stock Report

Market Cap: US$104.7m

Inovio Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 4/6

Inovio Pharmaceuticals has a total shareholder equity of $73.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $107.1M and $33.5M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$84.80m
EquityUS$73.54m
Total liabilitiesUS$33.52m
Total assetsUS$107.06m

Recent financial health updates

Recent updates

Here's Why We're Watching Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation

Aug 11
Here's Why We're Watching Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation

Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

May 15
Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

May 13
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

Oct 23
Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug

Oct 13

Inovio Pharmaceuticals: Long On Promise, Short On Results

Sep 27

Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M

Aug 09

Inovio: After All These Years

Jul 19

Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022

Apr 15

Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?

Mar 21
Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?

Inovio Undervalued On Potential 2022 Catalyst

Jan 26

Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Dec 31
Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Inovio Pharmaceuticals: Forget The COVID Pump, And Keep Your Eye On The Oncology Side

Nov 18

Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Sep 24
Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Inovio: Simply Cannot Be Ignored

Sep 03

Financial Position Analysis

Short Term Liabilities: INO's short term assets ($91.3M) exceed its short term liabilities ($23.5M).

Long Term Liabilities: INO's short term assets ($91.3M) exceed its long term liabilities ($10.0M).


Debt to Equity History and Analysis

Debt Level: INO is debt free.

Reducing Debt: INO has no debt compared to 5 years ago when its debt to equity ratio was 194%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: INO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: INO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.5% each year


Discover healthy companies